Despite the benefits of the administration of the Drp1 inhibitor before cerebral ischemia, Zuo and colleagues showed that it led to a deterioration in neurological function in permanent MCAO (pMCAO) via increased infarct volume, ROS generation, and apoptosis [11]. The gene discussed is DNM1L; the disease is brain ischemia.